. . . "2015-01-22+01:00"^^ . "Monoclonal gammopathy of undet" . " multiple myeloma" . "http://www.isvav.cz/projectDetail.do?rowId=NT14393"^^ . " low-dose multidetector CT" . "Signalling pathways in myeloma bone disease"@en . . " bone metabolism parameters" . "2013-05-01+02:00"^^ . "1"^^ . "1"^^ . . "2"^^ . "2"^^ . "0"^^ . "2014-03-21+01:00"^^ . " nuclear factor kappa B" . . "2015-12-31+01:00"^^ . " Runx/CBfa1" . "N\u00E1pln\u00ED projektu je zlep\u0161en\u00ED diagnostiky a monitorov\u00E1n\u00ED MKN s up\u0159esn\u011Bn\u00EDm indikac\u00ED antiresorp\u010Dn\u00ED l\u00E9\u010Dby. K posouzen\u00ED vhodn\u00FDch cytokin\u016F a chemokin\u016F (sclerostin, NF-kB, TRAP-5a, SDF-1, Runx2/Cbfa1, sFRP, Activin A, Annexin 2, p62, MMP-9) bude vyu\u017Eito dostupn\u00E9ho biologick\u00E9ho materi\u00E1lu (krevn\u00EDho s\u00E9ra a plazmy kostn\u00ED d\u0159en\u011B). Bude provedena korelace parametr\u016F kostn\u00EDho metabolismu se zobrazovac\u00EDmi technikami a histomorfometri\u00ED vzorku kostn\u00ED d\u0159en\u011B. Z\u00EDskan\u00E9 v\u00FDsledky budou slou\u017Eit k identifikaci jedinc\u016F s MGNV s vysok\u00FDm rizikem p\u0159echodu do symptomatick\u00E9 formy myelomu a k odhalen\u00ED skupiny nemocn\u00FDch, indikovan\u00FDch k \u010Dasn\u00E9mu nasazen\u00ED antiresorp\u010Dn\u00ED terapie je\u0161t\u011B p\u0159ed vznikem z\u00E1va\u017En\u00E9ho kostn\u00EDho posti\u017Een\u00ED podchycen\u00E9ho dostupn\u00FDmi modern\u00EDmi zobrazovac\u00EDmi technikami. U jedinc\u016F s MM budou v\u00FDsledky slou\u017Eit k vy\u010Dlen\u011Bn\u00ED skupin nemocn\u00FDch vy\u017Eaduj\u00EDc\u00EDch specifickou antiresorp\u010Dn\u00ED terapii (bisfosfon\u00E1ty) a skupiny, u n\u00ED\u017E nemus\u00ED b\u00FDt jej\u00ED dlouhodob\u00E9 pod\u00E1v\u00E1n\u00ED p\u0159\u00EDnosn\u00E9. C\u00EDlem je personalizovan\u00FD l\u00E9\u010Debn\u00FD p\u0159\u00EDstup se zlep\u0161en\u00EDm kvality \u017Eivota." . . . . "The aim of the project is to improve diagnostics and monitoring of myeloma bone disease with specification of the indications of anti-resorption therapy. For the assessment of convenient cytokines and chemokines we will use accessible biological material (blood serum and bone marrow plasma). In selected patients we will perform bone biopsy with the correlation of bone metabolism parameters with bone histomorphometry. The results will identify individuals with MGUS who are at high risk of transformation into asymptomatic and symptomatic MM, and to unravel a group of patients who should be indicated for early administration of anti-resorption therapy (bisphosphonates) before the development of bone involvement assessable by temporary imaging methods. In patients with MM the results will help to differentiate groups of individuals with different severity of skeletal involvement, depicting also patients who do and who possibly do not profit from prolonged bisphosphonates administration in MM remission."@en . "Sign\u00E1ln\u00ED dr\u00E1hy u myelomov\u00E9 kostn\u00ED nemoci" . " myeloma bone disease" . " SDF 1-alpha" . "Monoclonal gammopathy of undet; multiple myeloma; myeloma bone disease; bone metabolism parameters; nuclear factor kappa B; sFRP; SDF 1-alpha; Runx/CBfa1; low-dose multidetector CT, bon"@en . . . . . " sFRP" . . . . "NT14393" . .